...Health info at your doorstep

COVAX

Less Than 2% of Global COVID-19 Vaccines Administered in Africa

Less Than 2% of Global COVID-19 Vaccines Administered in Africa

Coronavirus, COVAX, NEWS
  The WHO AFRO says more efforts are needed to scale up COVID-19 vaccination in the African Region as many African countries have barely moved beyond the starting line. According to it, less than two per cent of the world’s 690 million COVID-19 vaccine doses administered to date globally have been in Africa with limited stocks and supply bottlenecks putting the vaccines out of reach of many people in the region. Regional Director, World Health Organisation Regional Office for Africa (WHO AFRO), Dr Matshidiso Moeti, spoke during a virtual press conference on Thursday facilitated by APO Group. Director of Population, Ministry of Health, Morocco, Dr Abdelhakim Yahyane; and UNICEF Regional Director for Eastern and Southern Africa, Mr. Mohamed Malick Fall, were at the meeti
Russia’s Virology, Biotechnology Vector Developing Intranasal COVID-19 Vaccine

Russia’s Virology, Biotechnology Vector Developing Intranasal COVID-19 Vaccine

Coronavirus, COVAX
  The Russian State Research Center of Virology and Biotechnology Vector has started developing a new Coronavirus (COVID-19) vaccine in the form of nasal drops, an official said. Vector General Director Rinat Maksyutov said in an interview with Sputnik that the vaccine would help provide immunity right at the “entrance gate” of the infection, “Yes, we have started developing a vaccine in the form of drops, an intranasal vaccine. “The composition of the main active component of the vaccine will remain unchanged (same as that of the EpiVacCorona vaccine),” Maksyutov said. The vaccine will help develop immunity in the nasal mucous membranes, which can be described as the “entrance gate” of the infection, Maksyutov specified.   NAN
Britain Advises Alternative to Oxford/AstraZeneca COVID-19 Vaccine for Under-30s

Britain Advises Alternative to Oxford/AstraZeneca COVID-19 Vaccine for Under-30s

Coronavirus, COVAX, NEWS
Britain should give an alternative to Oxford/AstraZeneca's COVID-19 vaccine to under 30s where possible due to a "vanishingly" rare side effect of blood clots in the brain, Britain's vaccine advisory committee said on Wednesday. Officials said the benefits of the shot continued to outweigh its risks for the vast majority, after safety concerns spurred over a dozen countries in recent weeks to suspend use of the vaccine following reports linking it to a brain blood clotting disorder. Britain has kept using the shot throughout. Wei Shen Lim, chair of Britain's Joint Committee on Vaccination and Immunisation (JCVI), said that based on the available data and evidence, it was preferable for adults aged under 30 with no underlying conditions to be offered an alternative to the AstraZen...
EU Drug Regulator Finds Link between AstraZeneca Vaccine and Blood Clots

EU Drug Regulator Finds Link between AstraZeneca Vaccine and Blood Clots

Coronavirus, COVAX, NEWS
Europe's drug regulator on Wednesday, April 7th  found a possible link between AstraZeneca's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot and said it had taken into consideration all available evidence. "One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin," the European Medicines Agency (EMA) said. The findings come as a major hurdle in the global fight against the pandemic and a shift in the stance of the regulator, which had last week backed the vaccine and said there was no increased risk of blood clots in general from the shot. It is also a blow to AstraZeneca, which was a frontrunner in the rac